Clinical Trials

5 results for Bladder Cancer


Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations

  • Condition: Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
  • Intervention: Drug: afatinib, Drug: regorafenib
  • Study ID: NCT02795156
View Trial

Peking University First Hospital

  • Condition: Upper Tract Urothelial Carcinoma, Bladder Recurrence
  • Intervention: Drug: Pirarubicin
  • Study ID: NCT02740426
View Trial

Prospective Randomized Phase II Trial: Single Instillation Versus Long-term Prophylactic Intravesical Instillation of Pirarubicin in the Prevention of Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma

  • Condition: Intravesical Instillation
  • Intervention: Drug: pirarubicin(THP)
  • Study ID: NCT03030157
View Trial

A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)

  • Condition: Colorectal Cancer (CRC), Epithelial Ovarian and Fallopian Tube Carcinoma, Urothelial Carcinoma, Triple-negative Breast Cancer (TNBC), Pancreatic Cancer, Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM)
  • Intervention: Biological: NKR-2 cells
  • Study ID: NCT03018405
View Trial

Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients

  • Condition: Bladder Recurrence, Upper Tract Urothelial Carcinoma, Nephroureterectomy
  • Intervention: Drug: Pirarubicin
  • Study ID: NCT02923557
View Trial